Benzoxazine derivatives.
Abstract
Pyrido[1,2,3-de] [1,4]benzoxazine derivatives are described having the formula (1) wherein X is a halogen atom, R is a hydrogen atom or an alkyl group of 1 to 6 carbon atoms and Z represents mono-substituted, di-substituted or cyclic-substituted amino group which may contain a hetero atom and may have a substituent such as hydroxy, alkyl having 1 to 6 carbon atoms, amino, hydroxyalkyl having 1 to 6 carbon atoms or mono- or di-alkylamino having 1 to 6 carbon atoms in each alkyl moiety and the pharmaceutically acceptable salt thereof, having antibacterial activity.

Term
No projected expiry on record.
- Priority
- Filed
- Granted
- Today
7 claims: 7 independent, 0 dependent
- 1Reference Example Παράδειγμα ’Αναφοράς The compounds of this invention are effective antibacterial agents for the treatment of various infectious diseases such as urinary tract infections or infections of the mammalian respiratory tract including humans. These compounds are usually used for oral administration but may also be administered by injection or may be used externally depending on the type of disease being treated. Αι ενώσεις αύτής τής έφευρέσεως είναι άποτελεσματικοί άντιβακτηρίακοί παράγοντες διά:τήν θεραπείαν διαφόρων μολυσματικών ασθενειών δπως μολύνσεις τής ούροδόχου οδού ή μολύνσεις είς τά άναπνευστίκά όργανα θηλαστικών περιλαμβανομένβυ το® ανθρώπου. Αύταί αί ενώσεις χρησιμοποιούνται συνήθως διά χορήγησιν άπό το® στόματος άλλά δύνανται νά χορηγηθούν έπίσης δι’ενέσεως ή δύνανται νά χρησιμοποιηθούν δι’έξωτερικήν έφαρμογήν άναλόγως τού τύπου τής πρός θεραπείαν άσθεν^είας. For oral administration, the compounds may be used in a dose of between about 100 mg. up to about 1000 mg. in adult humans per day, usually at 100 mg. up to 600 mg, in the form of various pharmaceutical preparations such as tablets, capsules, pills, granules, syrups and the like which are well known in the art. Other preparations suitable for injection or external application may also be prepared by techniques known in the art. For example, pharmaceutical preparations may be prepared by a method known per se using suitable diluents, binders, disintegrants, masking agents and the like. Διά τήν χορήγησιν άπό τού στόματος, αί ενώσεις δύνανται νά χρησιμοποιηθούν είς μίαν δόσιν μεταξύ περίπου 100 χλστγρ. εως περίπου 1000 χλστγρ. είς ένήλικας ανθρώπους άνά ημέραν, συνήθως είς 100 χλστγρ. εως 600 χλστγρ., ύπό τήν μορφήν διαφόρων φαρμακευτικών παρασκευασμάτων δπως δισκίων, καψουλών, πδνεων, κόκκων, σιροπίων καί τών παρομοίων αί όποΐαι είναι καλώς γνωσταί είς τήν τεχνικήν. Ετερα παρασκευάσματα κατάλληλα δι’ενεσιν ή έξωτερικήν έφαρμογήν δύνανται έπίσης νά παρασκευασθούν διά τεχνικών γνωστών είς τήν τεχνικήν. Π.χ., φαρμακευτικά παρασκευάσματα δύνανται νά παρασκευασθούν διά μιάς μεθόδου γνωστής άφ’έαυτής μέ χρήσιν καταλλήλων άραιωτικών, συνδετικών, άποσαθρωτικών, καλυπτικών παραγόντων καί τών παρομοίων. ./. ./. νAn example of a formulation containing compound (.aa) suitable for The administration of oral apd is described * '. · Ί · '-;· below: ί. * Capsules '* - »' ~ 3 · 'ό;·· c. ';Union (.Ia) 100.0 mg νΕνα παράδειγμα παρασκευάσματος παρασκευάσματος περιεχοντος τήν ένωσιν (.Ια) κατάλληλον διά χορήγησιν άπδ τοϋ στόματος περιγράφεται *’. ·ί ·' - ;· κατωτέρω : ί . * Κάψουλαι ' *-»'~3·'ό ;·· γ.’;'Ενωσις (.Ια) 100,0 χλστγρ. Maize starch 23.0 mg Αμυλον αραβοσίτου 23,0 χλστγρ. CMC 'Calcium 22.5 mg CMC ’Ασβέστιον 22,5 χλστγρ. Hydroxy propylmethyl cellulose 3.0 mg ‘Υδρόξυ προπυλομεθύλο σελλουλόζη 3,0 χλστγρ. Magnesium stearate 1.5 mg Στεατικόν μαγνήσιον 1,5 χλστγρ. Total 15θ χλστγρ.άνά κάψουλαι • · \ - ·· ό ?. '·'! ·: 'Ί' •• '' 'Λ'-6. * • - '. Λ ?? ·· λ ·: -;Λ - -. Σύνολον 15θ χλστγρ.άνά κάψουλαι • ·\ - ·· ό?.’·'!·:'ί '••'‘'Λ'-6 . * •-'.λ;;·· λ ·:-;Λ - - . ζ λ • »··· - .. ό · ζ λ • »··· --..ό· Although the invention is described in detail in reference to specific embodiments thereof, it will be apparent to one skilled in the art that various alterations and modifications may take place without departing from the spirit and mind. Παρά τό γεγονός δτι ή έφεύρεσις έχει περιγραφή λεπτομερώς έν άναφορδ πρδς συγκεκριμένος ενσωματώσεις της, θά είναι προφανές είς ενα έμπειρον είς τήν τεχνικήν δτι διάφοροι άλλαγαί καί τροποποιήσεις δύνανταί νά λάβουν χώραν ανευ άπομακρύνσεως άπδ τοΰ πνεύματος καί τοΰ σκοποΰ της. wherein X is a halogen atom, R is a hydrogen atom or an alkyl group of 1 to 6 carbon atoms and 2 represents a single substituted amino group, a bis-substituted / amino group or δπου X είναι ένα άτομον άλογόνου, R είναι ένα άτομον υδρογόνου ή μία άλκυλο ομάδα 1 εως 6 ατόμων άνθρακος καί 2 άντιπροσωπεύ/ι μίαν μόνο ύποκατεστημένην άμίνο όμάδα, μία δίς - υποκατεστημένη/αμίνο όιάδα ή -Λ >·. -Λ> ·. • ': dd ·'. '♦' · *.,. ϊ .. • ':dd ·' .' ♦' ·* .,. ϊ.. a cyclic-substituted amino group, and pharmaceutically acceptable salts thereof. μίαν κυκλικήν - ύποκατεστημένη άμίνο δμάδα, καί τά φαρμακευτικώς άποδεκτά αλατά της.
- 2A compound according to claim 1, wherein the substituent is selected from the group consisting of an aqueous group, an alkyl group. 2. Μία ένωσις δπως είς τήν άξίωσιν 1 , δπου δ ύποκαταστάτης εκλέγεται άπό τήν δμάδα τήν περιέχουσαν μίαν ύδρδξυ δμάδα, μία άλκύλο δμάδα 1 up to 6 carbon atoms, one amino group, one hydroxyalkyl group 1 to 6 carbon atoms and one monoalkylamino and one dicylamino group had from 1 to 6 carbon atoms in each alkyl moiety. 1 εως 6 άτόμων άνθρακος, μίαν άμίνο δμάδα, μίαν ύδροξυαλκύλο δμάδα 1 έως 6 άτόμων ανθρακος καί μίαν μονοαλκυλαμίνο καί μίαν διακλυλαμίνο δμάδα έχουσαν άπό 1 έως 6 άτομα άνθρακος είς έκαστον άλκύλο τμήμα.
- 3A compound as in Claim 1 or 2, wherein Z represents a single-substituted amino group selected from monoethylamine and monomethylamino, a bi-substituted amino group selected from one-cyano and a diethylamine selected from monoethylamine and diethylamine. up to 7 - core members selected from azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl and dmopiperazinyl. 3. Μία ένωσις δπως είς τήν ’Αξίωσιν 1 ή 2, δπου Ζ αντιπροσωπεύει μίαν μόνο- ύποκατεστημένην άμίνο όμάδα έκλεγομένην άπό μονοαιθυλαμίνο καί μονομεθυλαμίνο, μίαν δίς - ύποκατεστημένην άμίνο δμάδα έκλεγομένην άπό διαιθυλαμίνο καί διμεθυλαμίνο, καί μίαν κυκλικήν - ύποκατεστημένην άμίνο όμάδα:περιλαμβάνουσαν ενα 4- εως 7 - μελή πυρήνα έκλεγόμενον άπό άζετιδινύλο, πυρρολιδινύλο, πιπεριδινΰλο, μορφολινύλο, πιπεραζινύλο καί δμοπιπεραζινύλο.
- 4A compound according to Claim 1, wherein R is methyl and Z is methyl-1-piperazinyl. 4. Μία ένωσις δπως είς τήν 'Αξίωσιν 1, δπου R είναι μεθύλο καί Ζ -μεθύλο-1-πιπεραζινύλο. A compound as in Claim 1, wherein R is methyl and Z *; .v. ·? :: • / ί is * : ' · i · - 'X 5. Μία ένωσις δπως είς τήν ’Αξίωσιν 1, δπου R είναι μεθύλο καί Ζ *·.ν. ·? : : •/ί είναι * : ’ · i · - ’ X 5. is • 'n.C0 6. είναι •'n.C0 6. ::. ί • ·. · is ::.ί • ·. · εΐναι 7. 7. is· ι * '· · 8. είναι ή· ι * '· · 8. 4 t 4 t A process for preparing a 9-halogen-7-oxo-2,3-dihydro-7H-pyrido (1,2,3-des) (.1,4) benzoxazino-6-carboxylic acid compound of formula (I);*;'' * · '·:>' · * ·. · ·;·: '··. ·. Μία μέθοδος παρασκευής 9-άλογόνον-7-δξο-2,3-διϋδρο-7Η-πυρίδο(1,2,3-δε) (.1,4) βενζοξαζίνο-6-καρβοξυλικου όξέος ενώσεως τοϋ τύπου (I) · * ·’ '*·' ·:>' ·*·.· · ;·: '·· . ·. ' ·..-*· ,-;όπου R αντιπροσωπεύει, ενα ατομον ύδρογόνου ή μίαν άλκύλο δμάδα 1-6 άτόμων άνθρακος, Ζ άντιπροσωπεΰει μίαν μονο - ύποκατεστημένην άμίνο δμάδα, μίαν δίς - ύποκατεστημένην άμίνο δμάδα ή μίαν κυκλικήν - ύποκατεστημένην άμίνο δμάδα, και X είναι άτομον άλογόνου, ή όποία περιλαμβάνει θέρμανσιν ενός 9-άΟ-διαλογόνον-7-δξο-2,3-διΰδρο-7Η-πυρίδο (.1,2,3-δε)(1 ,1+) βενζοξαζίνο-6-καρβοξυλικού δξέος ή τοΰ 3-άλκύλο παραγωγού του μέ μίαν άμίνην άντιστοιχούσαν πρός τδν ύποκαταστάτην Ζ είς μίαν θερμοκρ: σίαν άπό περίπου 30°C εως 200°C. Wherein R represents, a hydrogen atom or an alkyl group of 1-6 carbon atoms;and X is a halogen atom, or which comprises heating a 9-dC-dialogon-7-oxo-2,3-dihydro-7H-pyrido (.1,2,3-d) (1,1 +) benzoxazino-6-carboxylic acid or 3- Alkyl of its derivative with an amine corresponded to the substituent Z at a temperature of from about 30 ° C to 200 ° C.
- 59. A process for the preparation of a compound of formula (i) as in Claim 8, wherein the substituent selected from the group consisted of a hydroxy group, an alkyl group of 1 to 6 carbon atoms, an amino group of a hydroxy group of a hydroxy group. carbon, and a monoalkylamino and a dialkylamino group had from 1 to 6 carbon atoms in each alkyl moiety. 9. Μία μέθοδος παρασκευής μιας ένώσεως τοΰ τύπου (ί) δπως είς τήν 'Αξίωσιν 8, όπου δ ύποκαταστάτης εκλέγεται άπό τήν δμάδα τήν περιλαμβάνουσαν μίαν ύδρόξυ δμάδα, μίαν άλκύλο δμάδα 1 έως 6 άτδμων άνθρακος, μίαν άμίνο δμάδα, μίαν ύδροξυαλκύλο ομάδα 1 εως 6 άτόμων άνθρακος, καί μίαν μονοαλκυλαμίνο καί μίαν διαλκυλαμίνο ομάδα έχουσαν άπό 1 έως 6 άτομα άνθρακος είς έκαστον άλκύλο τμήμα. 3 :/2/.7. / Ζ · d'ZZ-Z ··· <& -: -r ···· 3 :/2/.7. / Ζ· d'ZZ-Z ···<&—: -r ····
- 610. A process for the preparation of a compound of formula (i) as in Claim 8 or 9, wherein Z represents a single-substituted amino group selected from monoethylamino and monomethylamino, a bis-substituted amino group, and a substituted amino group;Substituted amino groups comprised a L + or 7-membered nucleus selecting aps azetidinyl, pyrrolioinyl, piperidinyl, morpholinyl, piperazinyl and homopiperazinyl. 10. Μία μέθοδος παρασκευής μιάς ενώσεως τοΰ τύπου (ί) δπως είς τήν 'Αξίωσιν 8 ή 9, δπου Ζ αντιπροσωπεύει μίαν μόνο- ύποκατεστημένην άμίνο δμάδα έκλεγομένην άπδ μονοαιθυλαμίνο καί μονομεθυλαμίνο, μίαν δίς - ύποκατεστημένην άμίνο δμάδα έκλεγομένην άπό διαιθυλαμίνο καί διμεθυλαμί νο, καί μίαν κυκλικήν ύποκατεστημένην άμίνο δμάδα περιλαμβάνουσαν ένα ί+ή 7- μελή πυρήνα έκλεγόμενον άπδ άζετιδινύλο, πυρρολιόινύλο, πιπεριδινύλο, μορφολινύλο, πιπεραζινύλο καί όμοπιπεραζινύλο.
- 711. A process for preparing a compound of formula (i) according to Claim 8, 9 or 10 wherein the heating is carried out at a temperature of 70 ° C to 130 ° C. 11. Μία μέθοδος παρασκευής μιάς ένώσεως τοΰ τύπου (ί) δπως είς τήν 'Αξίωσιν 8, 9 ή 10 δπου ή θέρμανσις διεξάγεται είς θερμοκρασίαν άπδ 70°C έως 130°C.
Independent claims7
421 paragraphs in 34 sections, as filed
Pi <sup>e</sup> ? _Ι-Γ _? _ Λ _ * _ ί _ ^ - 9_5ί ______ ϊ_Η_9_ϊ? _Ο _!? _ Α of the Japanese company DAIICHI SEIYAKU CO., LTD., With headquarters No. 14-10 NIHONBASHI 3-CH0ME, CHUO-KU, TOKYO, Japanese.
<img file="GR74637B_D0001.tif" />
Method of preparation of benzozazine derivatives.
'.'. Ρ ':'
Ά '©|| Ρά
<img file="GR74637B_D0002.tif" />
<img file="GR74637B_D0003.tif" />
. > -.ί ·. · ·· / <; · '· -? << 4 ·
<img file="GR74637B_D0004.tif" />
BACKGROUND OF THE INVENTION2
U.S. Patents. U.S. Patent Nos. 3,883,522; Japanese Patent Application (OPI) 133582/1979 describes 1-ethyl-6-fluhydro-7- (4-methyl-1-piperazinyl) -4-oxo-1,4-dihydrocyanyl-3-carboxylic acid , and Japanese Patent Application (OPI) 76875/1979 describes 8- (4-methyl-1-piperazinyl-9-fluhydro-5-methyl-6,7-dihydro-1-oxo-1H-5H-benz (.I j) quinolidine-2-carboxylic acid, (the term "CFI as used herein refers to a published patent application").
EPITOME<sup>1</sup> OF THE INVENTION The invention relates to a novel. antibacterial agent, and more particularly in 9-halide-7-oxo-2,3-dihydro-7-pyridone (1,2,3-d) (1,4) benzoxazino-6-carboxylic acid derivatives of formula (ΐ)
<img file="GR74637B_D0005.tif" />
where X represents α a halogen atom, R represents a hydrogen atom or an alkyl group having from 1 to 6 carbon atoms and Z represents a single-substituted amino group, a bis-substituted group or an amino to contain another hetero-atom, and the substituted amino dmase may further be substituted with one or more substituents selected from the group containing the hydroxyl; γγγ: .Ay • ·· ι · ..- ·. . · ··:? ·. Λ-yy '/ ·. '·· · - •• ii' !, // VS. ' V S- ·;
- '/ ·' ·. λ · ί
Ζ ..i * · *? ·· v<sup>;</sup>'S; S' - · Λ '«9->.' ··. <, ··. * ··: · *., · Ύ. \ τ '· *. ** -' · * WWi;
·;:·?>
* - AYY '/' '.آί • ..Pr: - ~ i i. <sup>;</sup>
Σ · <** ·. *? 4<sup>Λ</sup>'<Υ ·' ·
ΑαΎ'αΑ • ν '. ♦ * · yy • \' · 'ί' * A -V ,. '<sup>fc 5</sup> ,. · '·; -'. A ΥΥ
<img file="GR74637B_D0006.tif" />
alkyl 1 to c carbon atoms, amino, hydroxyalkyl 1 to 6 carbon atoms, monoalkylamino and dialkylamino had 1 to 6 carbon atoms in each alkyl moiety, and their pharmaceutically acceptable salts. Examples of the mn-substituted amino group include monoethylamino or monomethylamino, and examples of the bis-substituted amino group include diethylamino and dimethylamino, the azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl and homopiperazinyl (hexahydro1K-1, I + -diazepine-1-yl). Now, in particular, substituent Z means, for example, H-methyl-1-piperazinyl, 1-piperazinyl, 1-pyrrolidinyl,
3-hydroxy y-1 -pyrrolidinyl, 1 -periidyl, U-hydroxy-1 -pyridinyl,
3-hydroxy-1piperidinyl, in-morpholinyl, 4- (2-hydroxyethyl) πεkiperazinyl, 3,5- * dimethylds-1-piperazinyl, im-dimethylamino-1-piperidinyl-pyridol-homozylate di Nyl, 2-methyl-1-pyrazol di nyl, N- (2-hydroxyethyl) amino, N- (2-hydroxyethyl) -N-methylamino, hydrazyl and methylhydrazyl.
The compound of the invention is formulated to an acid addition salt with an inorganic or organic acid such as hydrochloric acid, sulfuric acid, methanulfonic acid and the like, and is formed in the corresponding manner, such as carboxylic acid and carboxylic acid. Compared to the known compounds described above, the compounds of this invention now have excellent antibacterial activity against GRAM-negative and GRAM-positive bacteria, as well as less toxicity.
.. - Ύ. zyy. '·'> <♦ ·. '-i. «.' y · <·. '. ·> ·' ··
-, - '*' · ”''. · * Ϊ ΥΑ'Υ-: Λ yyy, -: - · »-; · ·.
<img file="GR74637B_D0007.tif" />
DETAILED DESCRIPTION OF THE EFFORT22
The compounds according to this invention may be prepared by the reaction illustrated below.
': ·· · V
a. '·
777 (/
<img file="GR74637B_D0008.tif" />
GOOH
<img file="GR74637B_D0009.tif" />
COOH (II)
7/7.
: iWK • r ...
? A8S:> οό · 7. / • τ * ·. <· · - ·. ' . -><sup>s</sup>-> Λ * ·: · '· • a · λ ·?' Λ ·<sup>:</sup>γ, *. · - · * ·. ·. -<sup>!</sup>. '' - - χίΐί-ΐ ·: * ·> ·· .. <,; /
- · .-? -.- να: - - .-: -.-. 1 (I). Λ ', - .ΐ:,. ·. ·.
'·.: * /'; - · ί »·. ·. .— -ra-J '. · -. ·. ,:
Where X, R and Z are the same as described above. The reaction can be carried out by heating a compound of formula type. (ii) with an amine of formula (ill) at temperatures from about JO ° C to 200 ° C, and preferably from 70 ° C. up to 150 ° C, in the presence of a suitable organic polar solvent such as dimethyl sulfoxide, sulfolane, dimethylformamide, dimethylacetamide or water. It is desired that the reaction be carried out in the presence of an acceptable acid such as triethylamine, dimethylaniline, potassium carbonate and the like in a molar ratio of 1.0 to 1.2 molecules of the acceptable acid per molecule of the compound. Since the starting material of formula (III) is an amine, it can also act as an acid acceptor. In this case, the use of two or more amine molecules of formula (III) is required prior to one molecule of the compound of formula (ΐΐ). When another acid acceptor such as triethylamine is used, it is sufficient to use the amine of formula (ill) in a ratio of 1.0 to 1.2 molecules per molecule of the compound of formula (II).
<img file="GR74637B_D0010.tif" />
• <sup>Ί</sup>· *
<img file="GR74637B_D0011.tif" />
i ·. · -. · · • '> 6
<img file="GR74637B_D0012.tif" />
ϊ-.
The reaction is usually completed in a period of 1 to 3 hours and the product can be isolated and purified by standard techniques such as distillation, filtration, extraction, chromatography, recrystallization and combination. For example, when the product is precipitated by cooling the reaction mixture, it is collected by filtration and when it is not precipitated, the reaction mixture is concentrated to dryness under reduced pressure and the residue is stirred with a mixture of chlorinated products. chloroform layer. In case the product is stained or contains some by-products, further purification may be performed by SILICA GEL chromatography or recrystallization.
The starting compounds of formula (II) of the process for. The preparation of the compound of this invention are new compounds and can be prepared from a known compound; (A) (J. AKER. CHEM. SOC., 8t. 9U-101 0959)) by the following method. - '' • ·%, Μ <έ <
<img file="GR74637B_D0013.tif" />
I
I,
Γκ · -. '. ·
<img file="GR74637B_D0014.tif" />
gSjgg?
- Γ · ._ '·? · <
Υ. '*> **> ♦ · * · 5¾ ·. ·. *' · Ϊ; * ^ '··· ^. · *> <
7- \ - · V * \ '„• *'<sup>r</sup>. ' . *’«
In the formula, X represents a halogen atom.
When 2,3,4-trihalononitrobenzene (A.) is hydrolyzed in the presence of potassium hydroxide. triethylamine and the like, 2,3-dialogon-6-nitrophenyl (B) is produced. Compound (b) is heated with 1,2-dialogetoethane at temperatures from about 5 ° C to about 150 ° C, and preferably from 80 ° C to 120 ° C, while stirring in an organic polar solvent such as ethanol, dimethylformamide. or dimethylsulfoxide in the presence of an acceptable, inorganic base, e.g. potassium carbonate and sodium carbonate, or an organic base, e.g. triethylamine and N, N-dimethylaniline, to produce a compound of formula (G). The nitrate of compound (b) is then reduced by a common reduction using sodium sulfite or iron-hydrochloric acid or by RANEY catalytic reduction, and the compound of formula (j) is produced. When the compound (p) is heated to a temperature of about 50 ° C<sup>θ</sup>Up to 150 ° C in the presence of an acceptable acid which is used in the treatment of (B) (G), in a polar solvent such as ethanol or dimethylformamide, a benzoxazine derivative (E) is obtained. The benzoxazine derivative (e) is heated with diethyl ethoxymethylene nalonate from about 80 ° C to 150 ° C in the presence of a solvent such as ethanol or in the absence of a solvent to produce compound (P). At temperatures from about 120 ° C to 150 ° C in polyphosphates or esters thereof, the tricyclic compound (i) is prepared. The ester portion of the compound β1) is hydrolyzed by a standard method using an aqueous or base, and the starting compound of formula (ΐΐ) is obtained wherein the substituent R is hydrogen. Compounds (B) to (G) are also new compounds;
In the case where the substituent R in τ> ν (ΐΐ) is alkyl, the starting material of type (ΐΐ) is power; '*. ~ · Ιζφ ·:
Friday
<img file="GR74637B_D0015.tif" />
ε>
7.
<img file="GR74637B_D0016.tif" />
<img file="GR74637B_D0017.tif" />
.Λ;
·--¾¾¾¾
V; .. ·. <: * ·:.: -. ·. ·? Ί '---. ·. · .- ·· ·. . -.,. 1: -.- j *; That is, the compound of formula (3) or as described above is heated with halo methyl alkyl ketone, such as monochloroacetone, from 50 ° C to 15 ° C in the presence of an acceptable acid such as potassium carbonate or carbon dioxide or carbonate. , preferably in the presence of a catalytic amount of potassium iodide to produce a compound of formula (h).
<img file="GR74637B_D0018.tif" />
<img file="GR74637B_D0019.tif" />
'' When the compound (#) is catalytically treated with RANEY nickel or palladium on carbon, or the reduction of the nitro group, the closure of the ring by removing water from the resulting amino group and the oxo group and the oxygen group and the water take place. and a compound of formula (C) is obtained.
..-=-:/-2¾¾
.. '.- --ί ·:
<img file="GR74637B_D0020.tif" />
- 7-77. , τ ·. . · ·. & · <-
<img file="GR74637B_D0021.tif" />
* The union. s (.J) may be converted to the starting material of formula (iii) wherein the substituent R is alkyl according to the method of cases where R is hydrogen.
*-?;/··<?
<img file="GR74637B_D0022.tif" />
<img file="GR74637B_D0023.tif" />
. - * \ »· ''. ♦ Ay .- 'ό.
* i ··? **? · '
... ..
<img file="GR74637B_D0024.tif" />
<img file="GR74637B_D0025.tif" />
2>
3*.
ss
-.2279
<img file="GR74637B_D0026.tif" />
The antibacterial activity (IN VIjRO) of the compounds of this invention 9-fluoro ^ 0— (1 + -methyl-1-piperazyl) -3-methyl-7-oxo-2,3-dihydro-7H-pyrido. 1,2,3-de) (1,1+) benzoxazino-6-carboxylic acid (a), 9-fluhydro-3-methyl-7-oxo-10- (ΐ -piperazinyl) -2,3 -hydro-7H-pyrido (.1,2,3-des) (1,1+) benzoxazino-6-carboxylic acid (d6), 9-fluoro-1O- (3-hydroxy-1-pyrrolidinyl) -3- methyl-7-oxo-2,3-dihydro-7H-pyrido;
(.1,2,3-de) (1,1+) benzoxazino-6-carboxylic acid (1C), and 9-chloro-3 ~ methyl-10- (ΐ + -methyl-1-piperazinyl) -7 ζο dzo-2,3-dihydro-7H-pyrido (1,2,3-d) (1,1+) benzoxazino-6-carboxylic acid (1D) is shown in the following Table 1 and 2 comparing pipemidic acid (8-ethyl-5,5-dihydro-5 "oxo-2- (ΐ-piperazinyl) -pyrido (2,3-d) pyrimidine-6-carboxylic acid, a known antibacterial drug (abbreviated) · · ·, · · J
PPA. © Ις τδν Table 1).
·/.
<img file="GR74637B_D0027.tif" />
• i
<img file="GR74637B_D0028.tif" />
<td>VIRUS</td><td></td><td></td><td></td><td>co</td><td></td><td> 00</td><td>The</td><td></td><td>co</td><td>VIRUS</td>
<td>THE</td><td>C-4</td><td>ι — 4</td><td>ι — 4</td><td></td><td>CM</td><td>Γ--</td><td><Ο</td><td>ι — 1</td><td>Γ-</td><td>THE</td>
<td> •</td><td> •</td><td> •</td><td> •</td><td> •</td><td> •</td><td> •</td><td> •</td><td> •</td><td> •</td><td> •</td>
<td>The</td><td>The</td><td>The</td><td>The</td><td>The</td><td>The</td><td>The</td><td>r — 1</td><td>THE</td><td>The</td><td>THE</td>
Γ *<sup>:</sup> · '«': Ζ - - .λ ..
U / <3>
-48RB ,; - V .. * · ·
·. ...-. · ', <<;> ** - · ώ'<sup>1</sup>«'··; 'Α'- ί ·
- '* ·· · JS ,; ·. ί »- ·> Ft. * £ 4v '·. · *> · * .. · 'χ -,:. ·> * ♦. · • .-. ν. * ', - 7 tt', ν · £ \ · 7
X
THE
Ο <<
Ο,>
THE
Ο <<
<*
V ω
THE
THE
Ο ti w
Q
THE
U
THE
Q
H>
<sup>χ</sup>ω
X>
THE
P.
THE
Ο ν-Α>
Ο <<
ρα nJ <
cx <
JX,
<td>CM</td><td>VIRUS</td><td>LO</td><td></td><td>σν</td><td></td><td>ΟΟ</td><td>CO</td><td></td><td>σ></td><td>VIRUS</td><td>The</td>
<td>THE</td><td>The</td><td>σ</td><td>ι - ϊ</td><td>to</td><td>CM</td><td>Γ- »</td><td>r—</td><td>VIRUS</td><td>tO</td><td>ι - 4</td><td>ro</td>
<td>THE</td><td>The</td><td>The</td><td>The</td><td>The</td><td>THE</td><td>The</td><td>The</td><td>CM.</td><td>The</td><td>ro</td><td>The</td>
<td>V11</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>γ-4</td><td></td><td></td><td></td>
<td>CM</td><td>VIRUS</td><td>VIRUS</td><td></td><td></td><td></td><td></td><td>THE</td><td>cn</td><td>νθ</td><td></td>
<td>The</td><td>The</td><td>The</td><td> (—1</td><td>CM</td><td>γ - 4</td><td>CM</td><td>VIRUS</td><td>to</td><td>virus</td><td>CM</td>
<td>The</td><td>The</td><td>The</td><td>The</td><td>The</td><td>THE</td><td>THE</td><td>r-4</td><td>The</td><td>rH</td><td>THE</td>
V »νο
VIRUS
<td>νθ</td><td>νθ</td><td>virus</td><td>VIRUS</td><td>νθ</td><td>virus</td><td></td><td></td><td></td><td></td><td>VIRUS</td>
<td>VIRUS</td><td>VIRUS</td><td>CM</td><td>CM</td><td>VIRUS</td><td>CM</td><td></td><td></td><td>VIRUS</td><td></td><td>CM</td>
<td> «</td><td> •</td><td> •</td><td> •</td><td> ’ *</td><td> •</td><td></td><td></td><td> •</td><td></td><td> •</td>
<td>Earth</td><td><-κ</td><td>νθ</td><td>νθ</td><td>γ — 4</td><td>νθ</td><td>VIRUS</td><td>THE</td><td>CM</td><td>THE</td><td>The</td>
<td></td><td></td><td></td><td></td><td></td><td></td><td>CM</td><td>THE</td><td>ι — 1</td><td>The</td><td></td>
»—4 Λ ο
ο nJ • Η
Ο • Η μ ·
THE
U ω
The
<td></td><td></td><td></td><td></td><td></td><td></td><td>rO</td><td>. to</td><td>CK</td><td>νθ</td><td>to</td>
<td></td><td></td><td></td><td></td><td>r— (</td><td></td><td>νθ</td><td>γ — 4</td><td></td><td>to</td><td>ro</td>
<td>to</td><td></td><td></td><td>t ~ 4</td><td>THE</td><td>Earth</td><td>THE</td><td></td><td>σ></td><td>I</td><td>νθ</td>
<td>THE</td><td></td><td></td><td>o</td><td>The</td><td>The</td><td>CM</td><td>Ω</td><td>The</td><td>THE</td><td>The</td>
<td>VIRUS</td><td></td><td></td><td>in</td><td>CM</td><td>The</td><td></td><td></td><td>CM</td><td></td><td></td>
<td>VIRUS</td><td></td><td>c *</td><td></td><td>r-4</td><td>ro</td><td> *</td><td>► — ι</td><td></td><td> ·*</td><td>THE</td>
<td></td><td>r ^</td><td>co</td><td> . ·*</td><td></td><td>ι — 4</td><td>nJ</td><td>μ-1</td><td> *</td><td>r</td><td>THE</td>
<td> ·»</td><td>vO</td><td>CM</td><td>o</td><td> »</td><td></td><td>m</td><td></td><td>r</td><td>α></td><td>THE</td>
<td> 3</td><td> »—4</td><td>rH</td><td>GJ</td><td><υ</td><td> **</td><td>THE</td><td> *</td><td> 3</td><td>C</td><td> <</td>
<td>CM</td><td>ro<sub>#</sub></td><td></td><td>• H</td><td>ctf</td><td>r.</td><td>a</td><td>C3</td><td>THE</td><td>The</td><td></td>
<td></td><td></td><td> «*</td><td>c</td><td>The</td><td></td><td>♦ γ4</td><td>-THE</td><td>Κι</td><td>bO</td><td></td>
<td>•THE</td><td> *</td><td>in</td><td>o</td><td>nJ</td><td>Q)</td><td>ba</td><td>υ</td><td> 3</td><td>THE</td><td>r</td>
<td>Κι</td><td>V)</td><td>• H</td><td> £</td><td>THE</td><td>υ</td><td>THE</td><td>nJ</td><td>nJ</td><td>X</td><td>· Γ4</td>
<td>THE</td><td>• i — 4</td><td>rH.</td><td></td><td>ι-4</td><td>r</td><td>h</td><td>Ρ <</td><td></td><td> 04</td><td>τ — 4</td>
<td>C</td><td>Ki</td><td>• H</td><td>o</td><td>υ</td><td>α></td><td> 0)</td><td>4ϋ</td><td>r</td><td></td><td>· Ι-4</td>
<td>X</td><td>nJ</td><td>XI</td><td>c;</td><td></td><td>υ</td><td>α3</td><td>ω</td><td> 3</td><td>r</td><td>K"</td>
<td>The</td><td>oo</td><td>nJ</td><td>Λ</td><td>K"</td><td>K.</td><td></td><td></td><td>The</td><td> 3</td><td>χ></td>
<td>r — 4</td><td>r — 1</td><td></td><td></td><td>The</td><td>nJ</td><td>r</td><td>r</td><td>The</td><td>υ</td><td> 3</td>
<td>m</td><td> □</td><td>• H</td><td>nJ</td><td>-Hey</td><td> £</td><td>nJ</td><td>nJ</td><td>The</td><td>The</td><td>r</td>
<td></td><td> ></td><td>e</td><td>Earth</td><td>The '</td><td></td><td>C</td><td>G</td><td>The</td><td>The</td><td></td>
<td>nJ</td><td></td><td></td><td>ι-Η</td><td>nJ</td><td>nJ-</td><td>THE</td><td>THE</td><td>The</td><td>The</td><td>r</td>
<td>rH</td><td></td><td>in</td><td>THE</td><td>Χ></td><td>• r4</td><td> £·</td><td> £</td><td>ι — 4</td><td>The</td><td> 3</td>
<td>r — 4</td><td> 3</td><td>O</td><td>•THE</td><td>THE</td><td>Κ></td><td>THE</td><td>The-</td><td>X</td><td>+ J</td><td> »—4</td>
<td>O</td><td>Q></td><td>o</td><td>r</td><td>Κι</td><td> 03</td><td>The</td><td>XS</td><td>Γ—</td><td>Λ '</td><td>ι-4</td>
<td>on</td><td> 4-></td><td>K></td><td>-THE</td><td><ϋ</td><td>Κι</td><td>THE</td><td>The</td><td>'ω</td><td>THE</td><td>• THE</td>
<td>• H</td><td>o</td><td>o</td><td>THE</td><td>K "</td><td>Κι</td><td>THE</td><td>The</td><td>ηί</td><td>Κι</td><td>υ</td>
<td>X2</td><td></td><td>u</td><td>γ - ι</td><td>a</td><td>THE</td><td>r</td><td>r</td><td> +-></td><td> +-></td><td>nJ</td>
<td>CO</td><td>(X</td><td>CK</td><td>tei</td><td>W</td><td> €0</td><td>CX.</td><td>CL,</td><td>ω</td><td>ω</td><td>P4</td>
ον ί
'. - · '· -, ·' Γ. <Ν? ····. ·. << · «·: ί- ~ '' * · '/ ··.«' <·· α '* - · “·.<sup>1</sup> V. · * · '-. · »· *?>. ·? > 7 ·: /···*.·? ·· * '<·' ·· υι σ
ω £
The
CL ω
Phi
THE
-Α ω
ζΧ
ST
X
LP
Ο * -Α
THE.
-Α σ
THE
W υ>
1ST
X ~ Λ
7>
ϋ σ
M>
The
The.
THE
Ζ>
\ υ
X
The
THE
U> \ J> 3 σ ω Q. Ο ϊ3 ο
X CO ί- τω
Ο- £ σ -ω> - ·· ία α ο α Γ— -> ΚΑ ω ία. -J 'ω ω
U>
υ>
? cr
The o
ο <5
Κ) φ
W
3L υ »ίί =“
X <> - <ο ο Ο X C.
C * φ υ
υ> * σ α 3 * -> £ ω * w>
Cl v-> w ο
- »ο X Ο ο« 0 Η Hj
U> -3
U
Η -ω * - »£ * w>
The
Ο {= ·
Phi
THE
The
-»
Ο <2Χ ω
THE
<img file="GR74637B_D0029.tif" />
Π C να ζ
<img file="GR74637B_D0030.tif" />
As shown in Tables 1 and 2, the compound of this invention has higher antibacterial visibility over the tested organisms than the known drug. In addition, the compounds of this invention exhibit very low toxicity. Eg or acute toxicity (LD ^<sub>q</sub>) of compound (a) is 380 mg. / kg, on mice (eg).
On the other hand, known compounds, such as 8- (4-methyl-1-piperazinyl) -9f6dro-5-methyl-6,7-dihydro-1-oxo-1H, 5H-benz (L j) quinolizino-2 - carboxylic acid (Japanese Patent Application (OPI) 75875/1979) and 1-ethyl-6-fluoro-4-deoxy-7- (4-methyl-1-piperazinyl) quinoline-3-carboxylic acid (Japanese Application) Patent ( OP1) 138582/1979) have relatively high toxicity (or 35 mg / kg and 225 mg / kg, respectively, in mice ('ef)). * Although PPA has low toxicity k 610 to 6U9 mg. / kg in mice (eg)), or the antibacterial activity of PPA is much weaker than that of the compounds of this invention as shown in the Table above.
The present invention further illustrates all of the following Examples. Unless otherwise stated by the parties, one hundred percent, relationships and the like are by weight.
Example 1
Production of the starting material i gr. 2,3 N-Trifluoronitrobenzene was dissolved in 150 ml.
dimethyl sulfoxide, and to this mixture was added dropwise a solution of 10% potassium hydroxide while maintaining the temperature at 18 to 20 ° C. The mixture was then stirred for 2 hours at room temperature and one liter of water was added to this reaction mixture. and the mixture was stirred with chloroform. The aqueous phase was acidified with hydrochloric acid and extracted with chloroform.
and dried, then the chloroform phase; / ·
<img file="GR74637B_D0031.tif" />
/
<img file="GR74637B_D0032.tif" />
.....: //: 3 .: '//: • ·, .3 · <r<sub>w </sub>• . <
<img file="GR74637B_D0033.tif" />
. ·. '·. , -. f.
; . · I ”'- Ϊ- ·' - - ·, - * -.
· - · Il <* ··. r *.
'·· 7 7--- ·>'?;
<img file="GR74637B_D0034.tif" />
'»<? I. . · -T was purified by SILICA G3L column chromatography to give 5.8 g. 2,3-difluoro-6-nitrophenol as a yellow oil.
7.9 HP. 2,3-difluoro-β-nitrophenol, 50.1 g. 1,2-dibromoethane and 18.7 g. potassium carbonate was added to 80 ml. dimethylformamide and the mixture was stirred for 2.5 hours at about 80 to 100 ° C (bath temperature). The reaction mixture was concentrated to dryness in vacuo and the residue was partitioned between ethyl acetate and water. The residue was dissolved in benzene and purified by SILICA column chromatography. QEL διά να. yield 7.7 g. 2- (2-bromoethoxy) -3,4-difluoronitrobenzene as a pure yellow oil.
BMI (GDGlj): δ (m.a.e.). '
3.75 (2H, L, J = 7Hz, -CH<sub>2</sub>Br)
4.62 (2H, t, -OCHg-) '
6.92-7.04 and 7.65 ~ 7 »93 '. '-<sup>:</sup> · <sup>r</sup> 'c 6 (respectively Iff, a. 7 Gr-ff and C -ff);
1.74 gr. of this product were dissolved in 30 ml. methandyl and a solution of 6.44 MPa; sodium hyposulphite to 15 ml was added. Water .. The mixture was stirred for 1 hour at room temperature. The methanol was evaporated and the residue was extracted with chloroform. After washing, dilution with water and drying of the extract, the solvent was evaporated to give 0.44 g. 2- (2-bromoethoxy) -3,4-difluoroaniline.
NME CCLC1 ^ he (m.a.e.).
3.67. (2K, t, J = 6Hz, -CH<sub>2</sub>Br)
3.90 (2H, β, NH<sub>2</sub>)
4.42 <2H, t, J-6Hz, -0CH<sub>2</sub>-)
6.30 - 6.90 (2 ?, m, C<sup>5</sup>-ff and C<sup>S</sup>~ H).
<img file="GR74637B_D0035.tif" />
<img file="GR74637B_D0036.tif" />
<img file="GR74637B_D0037.tif" />
<sup>c</sup>7 ··? - 1/4 1, 82. gr. of this product and 3 »03 gr. potassium carbonate was added to 10 ml. dimethylformamide and the mixture was stirred for 1 hour at a temperature of about 80 to 100 ° C (bath temperature). The reaction mixture was added to ice-cold water and extracted with ethyl acetate; After rinsing with water and drying the extract, the solvent was distilled off at room temperature to give 1.21 g. 7,8difluoro-2,3-dihydro-4R- (ΐ, U) benzoxazine with m.p. 48—54 ° C.
<img file="GR74637B_D0038.tif" />
<img file="GR74637B_D0039.tif" />
'' 'J ·:
NMR (jCDGlj): δ (average)
3.38 (2H, t, J = 5.5Hz, -NHCH<sub>2</sub>-)
3.70 (IH, hs, NH)
4<sub>r</sub>28 (25, t, J »5.5 Hz, -0CH<sub>2</sub>-}
6.17 - 6.80 (2H, m, G<sup>5</sup>-H, C<sup>6</sup>-H).
The mixture 1.1 g. of this product and 1.38 MPa of diethyl ethoxymethylene nalonate were stirred for about 2 hours at about 130 to 135 ° C (bath temperature). * The ethanol produced was evaporated and 20 g was added to the residue. ' ethyl polyphosphate. The mixture was then stirred for 1.5 hours at about 11 + 0 to 145 ° 2 (bath temperature). The reaction mixture was added to ice-cold water and extracted with chloroform. The extract was completely quenched with Water. After drying, the solvent was evaporated and the residue was recrystallized from "ethyl acetate". 1.3 g were obtained. 9 "10-diphthro-7-dzo-2,3-dihydro-75 ~ pyrido (1,2,3-dc) (.1,4) benzoxazy τ. 2 & 5-266 ° C.
NMR (CRjCOOE): δ (average)
1.58 (3H, t, J »7.5 Hz, -CH<sub>2</sub>CH<sub>5</sub>)
4.76 (2H, s, J = 7.5 Hz, -CHgCHj)
4.96 (4H, bs, -CH<sub>2</sub>-CH<sub>2</sub>-)
8.17 (IH, q, 0<sup>&</sup>-THE)
9.35 (IH, e, G<sup>5</sup>-tt).
<img file="GR74637B_D0040.tif" />
<img file="GR74637B_D0041.tif" />
• - Λ ··.
···. · • ·. . · »'Λ ·' 'Ά / -آ
O.2 ».
ο · χ · ΧόΟΟΟ '. -t iA / O
VIRUS *
ίβ · - · “\ - μ ·· γ-ί *
-. · Λ * ·. ς • Λ'ςΑ. *; * -: /
Λ ', ί' · ./ · <sup>r</sup>R ... f> \:
,.'· ·'.'.
* - <sup>:</sup>Χ. ~ 'Πα · • Η' ·. ? *. '** · »·' ·· '.
<sub>r</sub>l5 gr. of this product were added to 12 ml. of a mixture of concentrated hydrochloric acid and acetic acid (1 L; by volume) and the mixture was stirred for U hours at 100 to 110 ° C (bath temperature). After cooling, ol precipitated crystals were collected by filtration, washed with water, methanol and chloroform to give 0.73 g. 9,10-difluoro-7 "oxo-2,3-ahydro-7H-pyrido (1,2,3-d) (1,1-U) -benzoxazino-6-carboxylic acid as colorless needle with mp above 3 ° C;
Found: G 53.31, V 2.75, N 5.26.
NMR (CI ^ COOH) i d (m.p.)
5.0 (itfT, b * at ·, -CHgCHg-),
8.17 Oa, α, ο<sup>8</sup>^) <sup>;</sup> · - - · .9Λ5 On, », c<sup>5</sup>-h). · Γγ, γ
Example 2
Production of starting material: „·
5.3 gr. 2,3 "dextro-6-nitrophenol, 5.0 g. Monochloroacetate, 8.0 g. Potassium carbonate and 0.3-g. Potassium iodide was added to 100 ml. Acetone and td the mixture was refluxed for 2+ hours. After removal. Of the insoluble material by filtration, the solvent was evaporated and the residue was partitioned between chloroform and water.The chloroform phase was washed with water and dried, then the solvent was evaporated, the residue was treated with n-hexane to give 5.0 g. 2-acetonyloxy υ-3> U-δι φθορ ον ιτρ οβεν ξενίου ως απηκοκτριβvτ crystals with mp 61 ° C.
7.1 HP. of this product were dissolved in 200 ml. ethanol and added to this mixture 11; χλστλ. nickel RANEY. The mixture was catalyzed under normal atmospheric pressure. After the removal \ ·.
'Ύ ·' · * *. ? ··? '' -
<img file="GR74637B_D0042.tif" />
• · AA
<img file="GR74637B_D0043.tif" />
Id
<img file="GR74637B_D0044.tif" />
<img file="GR74637B_D0045.tif" />
The residue was dissolved in chloroform and decolorized through a SILICA GSL column to give 5.1 MPa; 7,8-difluoro-2,3-dihydro-3-methyl-4K-benzoxazine as a light yellow oil.
The mixture 4.3 g. of this product and 5.3 TF; diethyl ethoxymethylene nalonate was heated for about 1 hour at about 140 to 145 ° C (bath temperature). After reflux, the ethanol produced was allowed to evaporate to give an oily product. 35 g of ethyl polyphosphate was added thereto and the mixture was stirred for 1 hour at about 10 ° C to 145 ° C (bath temperature). After cooling, the reaction mixture was added to ice-cold water. The precipitate was extracted. with 200 ml. chloroform, this treatment was performed three times, and the extracts were combined and washed with 5% potassium hydroxide solution and water. The chloroform phase was dried over sodium sulfate to give 5.1 g; 9,10-difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (1,2,3-des) 1,4) ethyl benzrxazino-6-carboxylate as a white powder mp 2 ° 1 ° C.
4.0 gr. of this product were diluted to 50 ml. in a mixture of concentrated hydrochloric acid and acetic acid (1: 4 by weight) and this mixture was refluxed for 3 hours in an oil bath. After cooling, the precipitated crystals were collected by filtration, washed thoroughly with water. The crystals were washed with a mixture of ethanol and ether (1/4 volume ratio) and dried in vacuo to give 3.7 g. 9,10-Difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (1,2,3-des) (1,4) benzoxazino-6-carboxylic acid as clear flakes with m.p. . above 300 ° C.
Example 3
<img file="GR74637B_D0046.tif" />
1.0 gr. 9,10-Difluoro-3-methyl-7-oxo-2,3-dihydro-7H- £ hyrido (.1,2,3-de) (.1,4) bexoxazine-6-carboxylic acid and 2.85 N-methylpperazine was added to 15 ml. dimethyl sulfoxide. It was stirred at a temperature of about 100 to 110 ° u (temperature l;
<img file="GR74637B_D0047.tif" />
··.
• ·; · ·. · •, Γ '·':
:. λ '. · ;. ·: Yyy / y: · '' 7777 • *. . ·. · «X W-;
for 12 hours and the reaction mixture was concentrated to dryness in vacuo and 40 ml was added to the residue. water. The product was then extracted with choroform. The extract was dried and concentrated to dryness in vacuo. The residue was recrystallized from ethanol to give 550 mg. 9 - φθδρο - 3<sup>-</sup>Methyl-1C- (4-methyl-1-piperazyl) -7-oxo-2,3-dihydro-7K-silicon (1,2,3-des) (1,2+) benzoxazino-6-carboxylic acid as colorless is mixed with mp 25 ° C-257 ° C (by decomposition).
Analysis for 8<sup>H</sup>2O<sup>FN</sup>3°<sup>i</sup>4; 'Calculated: G 59.82, H 5.58, N 11.63'
Found: G- 59.62, H 5.59, N 11, 65.
Example 4.
':: Zi: - * - · ϊ; · '?
. Λ: · '· ν ζ fi' · ίίΛί'Λ'.ϊ'-ν'ί; . · Ϊ'Λ ;. <··; λ ..:
12ψ0 χλστγρ. 9,1-di-rect »-3-methyl-7" δx "2,3-dihydro-7H-pyrido (1,2,3-des) (1,4) benzoxaxino-6-carboxylic acid and 404 mg. P-hydroxypiperidine was added to 2 ml. dimethyl sulfoxide. The mixture was stirred at a temperature of about 100 to 110 ° C (bath temperature) for 5.5 hours and the reaction mixture was concentrated to dryness in vacuo. The residue was added to water and the mixture was neutralized with dilute hydrochloric acid to give a precipitate. The sediment collected. by filtration, washed with water, and then recrystallized from ethanol to give 66 mg. 9-fluoro-10- (4-hydroxy-1-piperidinyl) -3-methyl-7-oxo-2,3-dihydro-7H-pyrido (1,2,3-des) (1,1H) benzoxazino-6 -καρβοξυλικοϋ δ ^ έος μέ σ.τ. 220-240 ° G (by decomposition). . >
Analysis for Cj gH ^ FN ^ O ^
Calculated: C 59.66, H 5.29, N 7.73;
Found: i '59 .24, W 5.26, N 7.65.
Example 5 .-;
<img file="GR74637B_D0048.tif" />
<img file="GR74637B_D0049.tif" />
<img file="GR74637B_D0050.tif" />
'?:··. :·
843 χλστγρ. 9,10-Difluoro-3-methyl-7-oxo-2,3-dihydro-7K-pyrido (1,2,3-des) (1,4) benzoxazino-6-carboxylic acid caizzo mg. 3-Hydroxypyrrolidine was addedto 10 ml. dimethyl sulfoxide.
<img file="GR74637B_D0051.tif" />
Ci
<img file="GR74637B_D0052.tif" />
<img file="GR74637B_D0053.tif" />
ζ - * '· · <
-λ: it ..
The mixture was stirred at about 100 to 110 ° C (bath temperature) for 1 hour and the reaction mixture was concentrated to dryness in vacuo. The residue was added to the residue and the insoluble matter was collected by filtration. * The substance was recrystallized from a mixture of chloroform and ethanol to give 45 mg. 9-fluoro-10- (3-hydroxy-1-pyrrolidinyl) -3-methyl-7-oxo-2,3-dihydro-7H-pyrido (1,2x3 ”and) carboxylic acid with m.p. 27S-280 ° C (by decomposition).
'Analysis for' Calculated: C 58/1, H 4.92, N 8.04 '
Found: C 58.45, H 5.10, N 7.94 "
Example 6
In this way, as in Example 3, 9-fluoro10- (or dmopiperaxy nyl) -5-methyl-7-oxo-2,3-dihydro-7H-pyrod (1, 2., 3- de) (1.4) <benzoxazino-6-carboxylic acid with m.p. 23O-234 ° G (by decomposition). This product was dissolved in dilute hydrochloric acid and the solution was concentrated in vacuo. To the residue, ethanol was added. The precipitated crystals were collected by filtration and washed with ethanol to give 9- * fluoro-10- (t-dopiperazinyl) -3-methyl-7-oxo-2,3-dihydro-7R (1,2-dihydro-hydroxy) hydrochloride hydrochloride. ~ δ «) (ΐ, 4) benzoxaxino-6-carboxyxic acid with wheat. 285r-29O ° C (by decomposition).
Analysis by C<sub>ia</sub>^ N ^. EC0. Η ^ Ο? Calculated C 51.99, K 5.57;<sup>Γ</sup> Found: 051/1, H 5/5, N 10.10.
Example 7
133 χλστγρ. 9,10-difluoro-7 "oxo-2,3-dihydro-7H-pyro (.1,2,3-des) (1.4) benzoxazino-6-carboxylic acid and 0.2 ml. Methylhydraxine was added to 3 ml. Dimethylformamide The mixture is stirred at a temperature of from about 100 to 11 ° C (temperature
The reaction mixture was concentrated to dryness in vacuo
<img file="GR74637B_D0054.tif" />
<. , ι
Υ · ,.
, λλ> υτροΰ) έπί 7 ساعت ς, .καί τδ'υπόλειμμα
<img file="GR74637B_D0055.tif" />
· <:? ·· v<sup>;</sup> : -* ·-?; ·
<img file="GR74637B_D0056.tif" />
<img file="GR74637B_D0057.tif" />
<img file="GR74637B_D0058.tif" />
·. * W <· * /
<img file="GR74637B_D0059.tif" />
treated with water. * The insoluble matter was collected by filtration and recrystallized from ethanol to give 30 mg. 9-fluhydro-10- (dimethylhydrazyl) -7-oxo-2,3-dihydro-7H-pyrido (.1,2,3-d) (1,4) benzoxazino-carboxylic acid as yellow prisms with mp. 239-242E<sup>P</sup>C.
Analysis by, ^ ΊΊΓ ^ Ο ^
Calculated: C 53.24, H 4.13, N 14.33 *
Found: C 53.39, H 4.22, N 14.22.
Example 8
Production of the starting material:
1θ, 5 gr. 2,0-dichloro-3-fluoronitrobenzene (CO5) was dissolved in 30 ml. dimethyl sulfoxide, and 8 ml of the mixture were added to the mixture. in 10% aqueous sodium hydroxide solution, then the mixture was stirred at 60 to 70 ° C for 20 hours. After completion of the reaction, 200 ml were added. water and the unreacted starting material were removed by extraction with diethyl ether. * The aqueous phase was acidified with acetic acid and extracted with diethyl ether. The ether extract was dried over sodium sulfate and the ether was distilled off. The resulting residue was purified by SILICA CEL column chromatography (.100 g) using chloroform as eluent to give 3.4 MPa (35.5% yield) 3-chloro-2-fluoro-6-nitrophene. mp 73 °<sup>G</sup>·, * A mixture of 3 g. (15.7 mg) 3-chloro-2-fluhydro-6-nitrophenol, 3 ml. chlorofacetone and 300 mg. potassium iodide in 50 ml. acetone was refluxed for 6 hours while stirring vigorously. After cooling, any insoluble matter was removed by filtration, and the filtrate
<img file="GR74637B_D0060.tif" />
concentrated and purified by SILICA CEL column chromatography (20 g)
<img file="GR74637B_D0061.tif" />
<img file="GR74637B_D0062.tif" />
<img file="GR74637B_D0063.tif" />
,-.,/. · - - ·» 5-.
<img file="GR74637B_D0064.tif" />
2.3 gr. (7 "9 mg) of 2-acetonyloxy-4-chloro-3-fluoronitrobenzene were dissolved in 30 ml ethanol and reduced catalysts in the presence of 2 g nickel RANEY. After completion of the reduction, the catalyst was removed by filtration , and the filtrate was concentrated.The resulting residue was purified by flash chromatography on a SILICA GEL (20 g) using chloroform as eluent to give 1.2 g. (75> 5. & yield) 7-chloro-8-fluoro-3<sup>_</sup>methyl-2,3-dihydro-4H-1,4-benzoxazine as an oil.
* A mixture of 1.11 gr. (5.5 mg) 7-chloro-8-fluhydro-3-methyl-2,3-dihydro-4N-1,4-benzoxazine and 1.4 g. (6.2 mg) of diethyl ethoxymethylene nalonate was stirred for 2 hours while heating to 130-1 ° C (bath temperature). After confirming the disappearance of the starting compound benzoxazine by thin layer chromatography, 5 g of ethyl polyphosphate was added to the reaction mixture, and the mixture was allowed to react again for 1 hour at 14 ° C (temperature). After cooling, 20 ml were added. of water in the mixture and the resulting precipitate was extracted with 150 ml. chloroform. The chloroform extract was dried over sodium sulfate and then the chloroform was distilled off. The resulting residue was purified by SILICA GEL column chromatography (20 g) using methanol-chloroform (5:95 by volume) as eluent to give 1.2 g. (67% yield) 9-chloro-10-fluoro-3-methyl-7-oxo-2,3-dihydro-7B-cyrido - (^, 2,3-de) (1,1+) benzoxazino-6-carboxyl. ethyl alcohol at az.263-364 ° C.
Analysis for C ^ H ^ CtPNO ^ Calculated: C. 55.31, H 4.02, N 4.30 '
Found: C 55.19, H 3.97<sub>r</sub> N, 4.41.
<img file="GR74637B_D0065.tif" />
? ·. ··· χ '<sup>;</sup> ' -·-·
<img file="GR74637B_D0066.tif" />
600 χλστγρ. (1 mg / ml) of the above benzoxazine compound was dissolved in 5 ml. concentrated hydrochloric acid —ozei- (acid: .1: 1 + by volume) and the solution was heated at 120 ° C (bath temperature) for 6 hours. After cooling, 200 ml of the reaction mixture was added. water and the precipitated crystals were collected by filtration, washed thoroughly with water, ethanol - diethyl ether (m: 1 by volume) and then diethyl ether, and dried to cut 2 + 59 mg, 9 g -10-fluoro-3-methyl-7-oxo2,3-dihydro-7H-pyrido (1,3,3-de) (-1,2 +) benzoxazino-6-carboxylic acid m.p. > 300 ° C as transparent flakes.
Analysis for G ^^ Gt-P NO ^ 'Calculated t G 52, U5, H 3.05, N 2 +, 71'
Found: © 52.20; H 3.13; N 2 +, 72 +.
Example 9
150 χλστγρ. (0.5 mg) 9-chloro-1O-fluoro-3-methyl-7, • 'i.' t
Sox-2,3-dihydro-7H-pyrido (1,2,3-des) (1,2+) benzoxazino-6-carboxylic acid was suspended in 3 ml. dimethyl sulfoxide and 150 mg were added to the suspension. N-methylpiperazine. The mixture was then allowed to react at 12 ° C-13 ° C (bath temperature) for 6 h. After cooling, the solvent was distilled off under reduced pressure, and the residue was washed with diethyl ether to remove any insoluble matter. The resulting residue was purified by column chromatography, SILICA GEL (7 g)
<img file="GR74637B_D0067.tif" />
using methanol-chloroform (5 i 95 by volume) and then methanol-chloroform (10: 90 by volume) as eluents, and the resulting product was recrystallized from ethanol to give 65 mg. (32 +, 2 +% yield) 9-chloro-3-methyl-1 O- (2 + -methyl-1-piperazyl) -7-oxo2,3-dihydro-7K-pyrido (1,2,3- and (1, 2 +) benzoxazino-6-carboxyl + acid as light yellow thin needles with m.p. 275-27 ό ° ΰ (μέ ά ^ ιοσύνΦεσιν).
>/.
<img file="GR74637B_D0068.tif" />
<img file="GR74637B_D0069.tif" />
<img file="GR74637B_D0070.tif" />
<img file="GR74637B_D0071.tif" />
<img file="GR74637B_D0072.tif" />
Analysis for ^ -, 5 ^ 20 ^^ 3% Calculated: C 57.22, H 5 "3H, N 11.12 *
Found: C, 57.20; H, 5.11; N, 11.23.
ρ
Examples 10-32
Using treatments analogous to those described in
Example 3 or U above, the following products were obtained, which were crystallized from ethanol unless otherwise described:
10. 9-Fluoro-1H (P-methyl-1-piperazinyl) -7-oxo-2,3-dihydro-7E-pyrido (; 1,2,3-des) (.1, U) benzoxazino-6-carboxylic acid as light yellow arrows-yes with mp 260 - 27 ° C (dec.).
11. 9-fluoro-10- (N-2-hydroxyethyl-N-methylamino) -7-oxo-2,3-dihydro-7-pyrido Cl, 2,3-de) ¢ 1,1 +) benzoxazino-6-carboxylic acid as light yellow needles with mp 262-265 ° C ·
12. 9-ψ θ δρ ο-10- (3-ύ δρ όξ υ-1 -π ι πε ρα ζ ι ν ύλο) -7-δξ ο-2,3- δ ι ϋ δρ ο-7Ε-πυρ ί δ c 2,3-d) (1,1+) benzoxazino-6-carboxylic acid (crystallized from methandylene) as yellow needles with mp 270-277% (dec.).
15. 9-fluoro-10- (3-hydroxy-1-piperidinyl) -3 ~ methyl-7-oxo-2,3-dihydro7P-pyrido- (ΐ, 2,3-de) (<1, U ·) benzoxazine- 6-carboxylic acid as light yellow needles with mp 267-273% (dec.).
11 + · 9-fluhydro-7-oxo-10- (ΐ-piperazinyl) -2,3-dihydro-7H-pyrido (1,2,3de) (1H +) benzoxazino-6-carboxylic acid as light yellow needles with mp 258-268 ° C (dec.) (Crystallized from Water).
15 · 9-fluoro-3-methyl-10- (1 | -morformolinyl) -7-oxo-2,3-dihydro-7H-pyrido (1,2,3-d) (1,4) benzoxazino-6 - carboxylic acid as colorless needles with mp 3ΟΟ · '
16. 9-fluoro-3-methyl-7-oxo-10- (1-piperazinyl) -2,3-dihydro-7H-pyrido (1,2,3-d) (1H +) benzoxazino-6-carboxylate two to slightly yellowing white crystals with mp 260% (dec.).
17- 9-Phthoro-1 ((ΐ | - (2-hydroxyethyl) piperazinyl) 3-methyl-7-oxo-2,3 dihydro-7H-pyrido (1,2,3-des) (.1, 1 + benzoxazino -6-carbs λικ material acid with mp 282-285 ° C (dec.).
18. 9-fluoro-3-methyl-10- (D-piperidinyl) -7-oxo-2 ,, C7H-pyrido (1,2,3-des) (1,1+) benzoxazino-6-carboxyl 275% (from .).
·/.
<img file="GR74637B_D0073.tif" />
.5 < -. : .3-,.
- .|· · -. ·. ' ’*··
-
Λ
5555 . 1.- ··
Λ - .. 'Λγ' · Λ - ·. ': ~ Λ
-. 5:+ .'· -· 5' -+.
ry 5 '· +.
• f.- ~ · - - * V χ. .'S ·. ΛΕ * 5; .19. 10- (4-ethyl-1-piperaxyl nyl) -9 - <? 3oro-3-methyl-7-oxo-2,3-dihydro7H-pyrido (benzoxaz-no-β-carboxylic acid with mp 263.5 - 264.5 ° C;
20. 9- <rthro-3-methyl-7-oxo-10- (1-pyrrolidinyl) -2,3-dihydro-γE-pyrido (1,3,3-δ) (1,4) benzoxaz-no-6- carboxylic acid with mp 268-269 ° C.
21. 10- (4-Dimethylamino-1-mol for special nyl) -9-fluoro-3-methyl-7-oxo-2,3 dihydro-7H-pyro (1,3,3-δ) (1,4) benzoxaz -no-6-carboxylic acid with mp 245 - 248 ° C (dec.).
22. 10-dimethylamino-9-phtharo-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (1,2,3-des) (<sub>;</sub>1,4) benzoxazino-6-carboxylic acid with mp 233 235 ° C.
23-9-phthero-3-methyl-1H- (4-methyl-1-d & opiperazine nyl); , 4) benzoxaz-n-6-carboxylic acid with m.p. 254 ° 237 ° C (dec.).
24. 9- <Pluoro-3-methyl-10- (2-methyl-1-pyrazolidinyl) -7-oxo-2,3-dihydro-7H-pyro 1, (1,2,3-de .) (1,4) benzoxazophan-6-carboxylic acid with m.p. 233-23<sup>θ</sup>0·
25- 9- <orthhydro-3-methyl-7-oxo-10- (1-pyrazole dinyl) -2,3-dihydro-7Hypyrido (1,2,3-des) (1,4) -benzoxaz £ no-6-carboxylic acid with m.p. 215-225 ° C (dec.).
26. 9-fluoro-10- (3-hydroxy-1-azet dinyl) -3 ~ methyl-7-oxo-2,3-dihydro7E-pyrido (1,2,3-des) (1,4) benzoxaz £ no-6-carboxylic acid with m.p. 286-286.5 ° C (crystallized from chloroform-ethane).
27. 9-fluhydro-3-methyl-7-oxo-10- (4-thiamorpholinyl) -2,3-dihydro-7Hpyrido (1,2,3-des) (1,4) benzoxazo £ no-6-carboxylic acid with m.p.
> 300 ° C (crystallized from chloroform-ethane).
28. 9-fluoro-10- (3-Hydroxymethyl-1-pyrrolidinyl) -3-methyl-7-oxo-2,3 dihydro-7E-pyrido (1,2,3-des) (1,4) benzoxazone -6-carboxylic acid at mp 237 ° C (crystallized from chloroform - ethanol).
29. 9-fluoro-10- (2-hydroxymethylb1-pyrrolidivyl) -3-methyl-7-deoxo-2,3-dipo-7E-pyrido (1,2,3-des) (1,4) benzoxaz-no-6 -carboxylic acid with m.p. 265 ° C (crystallized from chloroform - ethanol).
30. 9-Ftero-10- (4-hydroxymethyl;) ΐ-piperidinyl) -3-methyl-7-oxo-2,3-
<img file="GR74637B_D0074.tif" />
¢., ;·-
<img file="GR74637B_D0075.tif" />
31.
r. · Ρ
·. r. '··?
9-fluoro-10- (3-hydroxymethyl-1-piperidinyl) -3-methyl-7-oxo-2,3 dihydro-7H-pyrido (1,2,3-des) (1,4) benzoxazino- 6-carboxylic acid with m.p. 222 ° C.
32. 10- (4-amino-1-piperidinyl) -9-fluoro-3-M · ethyl-7-oxo-2,3-di · ΰs-o-7Hpyrido (.1,2,3-δ) ( 1,4) benzoxazine no-6-carboxylic acid (after reacting the compound (II) with 4-tert-butoxycarbonyl aminopiperidine, the protected product was treated with trifluoroacetic acid to remove the tert-carboxylic acid. The final product contains crystalline water (3/2 HgO) and melts at 150-151 ° C at elevated temperature, then crystallizes at 170-180 ° C, and thaws again at 210-212 ° C).
Reference Example
Contents34
75 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12 Sheet 13 Sheet 14 Sheet 15 Sheet 16 Sheet 17 Sheet 18 Sheet 19 Sheet 20 Sheet 21 Sheet 22 Sheet 23 Sheet 24 Sheet 25 Sheet 26 Sheet 27 Sheet 28 Sheet 29 Sheet 30 Sheet 31 Sheet 32 Sheet 33 Sheet 34 Sheet 35 Sheet 36 Sheet 37 Sheet 38 Sheet 39 Sheet 40 Sheet 41 Sheet 42 Sheet 43 Sheet 44 Sheet 45 Sheet 46 Sheet 47 Sheet 48 Sheet 49 Sheet 50 Sheet 51 Sheet 52 Sheet 53 Sheet 54 Sheet 55 Sheet 56 Sheet 57 Sheet 58 Sheet 59 Sheet 60 Sheet 61 Sheet 62 Sheet 63 Sheet 64 Sheet 65 Sheet 66 Sheet 67 Sheet 68 Sheet 69 Sheet 70 Sheet 71 Sheet 72 Sheet 73 Sheet 74 Sheet 75
43 members in 24 offices
Priority claims4
| Document | Office | Kind | Date |
|---|---|---|---|
| 12154080 | Japan | A | |
| 12154080 | Japan | A | |
| 12154080 | – | – | – |
| JP19800121540 | – | – | – |
Members43
| Document | Office | Kind | |
|---|---|---|---|
| IL63613A0 | Israel | A0 | |
| IL63613D0 | Israel | D0 | |
| DK388981A | Denmark | A | |
| FI812693L | Finland | L | |
| NO812956L | Norway | L | |
| EP0047005A1 | European Patent Office (EPO) | A1 | |
| AU7487881A | Australia | A | |
| JPS5746986A | Japan | A | |
| ZA815604B | South Africa | B | |
| ES505116A0 | Spain | A0 | |
| ES8301977A1 | Spain | A1 | |
| US4382892A | United States of America | A | |
| AU529263B2 | Australia | B2 | |
| YU210981A | Yugoslavia, later Serbia and Montenegro (until 2006) | A | |
| KR830006303A | Republic of Korea | A | |
| NZ198224A | New Zealand | A | |
| CA1167840A | Canada | A | |
| GR74637BThis record | Greece | B | |
| IL63613A | Israel | A | |
| EP0047005B1 | European Patent Office (EPO) | B1 | |
| AT10282T | Austria | T | |
| ATE10282T1 | Austria | T1 | |
| KR840002141B1 | Republic of Korea | B1 | |
| DE3167216D1 | Germany | D1 | |
| IN155680B | India | B | |
| PH18276A | Philippines | A | |
| JPS6111955B2 | Japan | B2 | |
| FI71155B | Finland | B | |
| HK82186A | Hong Kong, China | A | |
| FI71155C | Finland | C | |
| MY8600712A | Malaysia | A | |
| DK204488A | Denmark | A | |
| DK204488D0 | Denmark | D0 | |
| NO158507B | Norway | B | |
| YU42422B | Yugoslavia, later Serbia and Montenegro (until 2006) | B | |
| NO158507C | Norway | C | |
| YU74788A | Yugoslavia, later Serbia and Montenegro (until 2006) | A | |
| DK158267B | Denmark | B | |
| DK158267C | Denmark | C | |
| YU47193B | Yugoslavia, later Serbia and Montenegro (until 2006) | B | |
| HRP930087A2 | Croatia | A2 | |
| SI8112109A8 | Slovenia | A8 | |
| BA97190B1 | Bosnia and Herzegovina | B1 |
Numbers
- Publication, DOCDB
- 74637
- Publication, EPODOC
- GR74637
- Application
- 65931
- Application, DOCDB
- 810165931
- Application, EPODOC
- GR19810165931
Titles
- English
- BENZOXAZINE DERIVATIVES
Classification
- CPC, 5
- C07C205/37
- C07D498/04
- A61P31/04
- C07D265/36
- C07D498/06
- IPC, 6
- C07D498 04
- A61K31 535
- A61P31 04
- C07C205 37
- C07D265 36
- C07D498 06